Ableism—discrimination against those with disabilities—distorts diagnostic reasoning & erodes patient trust. How can rheumatologists address this bias?
Search results for: health insurance
The Pros & Cons of AI
As the uses for artificial intelligence grow within rheumatology, so do the benefits and the concerns about the technology. In a session at ACR Convergence 2025, two experts discuss the research on both sides of the debate.
Meet New ACR President William (Will) F. Harvey
Incoming ACR President Will Harvey shares his strategy for fighting reimbursement cuts, funding threats & workforce shortages through advocacy & member engagement.
Rheumatology Influencers: Dr. Hirsh Advocates for Physicians & Patients
Dr. Marc Hirsch reflects on a career dedicated to advocating for physicians, providing patient-centered care & advancing medical education.
What Clinicians Should Know About Midfoot Osteoarthritis
Midfoot OA experts offer an overview of a common, but under-recognized, form of OA, & discuss quality of life impacts, treatments, clinical evaluation procedures & the critical need for further research.
Rheumatology Influencers: Dr. Dave Has a Passion for Giving Back
Dr. Amish Dave discusses how his volunteer, advocacy & public outreach work stem from his greater commitment to community & helping others.
3 AC&R Study Summaries: Avoidable RA Hospitalizations, Psoriasis to Psoriatic Arthritis Transition, & Neighborhood Conditions in Childhood Lupus
New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Medical Liability Reform Position Statement Now Addresses Harmful Payer Policies, Telemedicine Authorization & Patient Compensation
The largest changes include additions that address harmful payer policies, telemedicine authorization and patient compensation funds.
UHC Formulary Change Impacts Coverage for Ustekinumab
Effective Sept. 1, the brand name drug Stelara will no longer be covered on the UnitedHealthcare commercial plan prescription drug list.
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 118
- Next Page »